Abstract
Atherosclerosis is the major cause of heart attack and stroke that are the leading causes of death in the world. Nanomedicine is a powerful tool that can be engineered to target atherosclerotic plaques for therapeutic and diagnosis purposes. In this review, advances in designing nanoparticles with therapeutic effects on atherosclerotic plaques known as atheroprotective nanomedicine have been summarized to stimulate further development and future translation.
Highlights
Atherosclerosis is the thickening of artery vessel walls that can develop in arteries supplying blood to various organs such as heart, brain, and kidneys
Collagen is an important target for atherosclerotic lesions especially since collagen IV forms the bases of blood vessels and it gets exposed during atherosclerosis progression (Murata et al, 1986)
A comparison was made for low doses of [S]-reconstituted HDL (rHDL) (15 mg/kg simvastatin, 10 mg/kg apolipoprotein A (ApoA)-I) that was administered intravenously biweekly for 12 weeks vs. orally administered simvastatin (15 mg/kg per day) and the results showed lower plaque macrophage content for the [S]-rHDL group
Summary
Atherosclerosis is the major cause of heart attack and stroke that are the leading causes of death in the world. Nanomedicine is a powerful tool that can be engineered to target atherosclerotic plaques for therapeutic and diagnosis purposes. Advances in designing nanoparticles with therapeutic effects on atherosclerotic plaques known as atheroprotective nanomedicine have been summarized to stimulate further development and future translation. Specialty section: This article was submitted to Experimental Pharmacology and Drug
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
